Tanabe Research Laboratories USA Inc. and Mitsubishi Tanabe enter into a strategic collaboration and license agreement with Covagen for the development of bispecific FynomAbs

Tanabe Research Laboratories USA Inc. and Mitsubishi Tanabe enter into a strategic collaboration and license agreement with Covagen for the development of bispecific FynomAbs

Tanabe Research Laboratories U.S.A. Inc. (TRL) and its parent company Mitsubishi Tanabe Pharma Corporation (Osaka, Japan) have entered into a strategic research collaboration and license agreement with Covagen of Zurich Switzerland. Under the agreement, Covagen will use Covagen’s proprietary Fynomer-antibody platform to generate bispecific proteins (FynomAbs) against two target pairs selected by TRL and Mitsubishi […]

Read More »